Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Align TechnologyXTER:AFW +0.70%85 EV-to-EBITDA is 13.84 as of Aug. 02, 2026, which is 55% below its 10-year median of 30.78. GuruFocus rates XTER:AFW with a GF Score™ of 85/100 and a GF Value™ of €215.66 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 512 Medical Devices & Instruments companies, Align Technology ranks better than 53.32% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Align Technology's enterprise value is €9,632 Mil.
Align Technology's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €696 Mil. Therefore, Align Technology's EV-to-EBITDA for today is 13.84.
The historical rank and industry rank for Align Technology's EV-to-EBITDA or its related term are showing as below:
XTER:AFW'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 10.56 Med: 30.78 Max: 101.03
Current: 13.27
During the past 13 years, the highest EV-to-EBITDA of Align Technology was 101.03. The lowest was 10.56. And the median was 30.78.
XTER:AFW's EV-to-EBITDA is ranked better than 53.32% of 512
companies
in the Medical Devices & Instruments industry
Industry Median: 14.39
vs XTER:AFW: 13.27
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Align Technology's PE Ratio (TTM) for today is calculated as:
Align Technology's share price for today is €151.70.
Align Technology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.948.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Align Technology's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:AFW vs BAX, SOLV, COO: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Align Technology's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Align Technology EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Align Technology's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Align Technology's EV-to-EBITDA falls into.
Align Technology's current Enterprise Value is €9,632 Mil.
Align Technology's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €696 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Align Technology (XTER:AFW) has a EV-to-EBITDA of 13.84 as of Aug. 02, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Align Technology. This is 55% below median its historical median of 30.78. Over the past decade, Align Technology's EV-to-EBITDA has ranged from 10.56 to 101.03. According to the industry distribution chart, Align Technology ranks #239 out of 512 companies in the Medical Devices & Instruments industry, placing it in the top 46.7%.
Is Align Technology's EV-to-EBITDA too high?
Align Technology's current EV-to-EBITDA of 13.84 is 55% below median its 10-year median of 30.78. Over the past 10 years, this metric has ranged from a low of 10.56 to a high of 101.03. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.39. Align Technology's value of 13.84 is 3.8% below this industry median. Based on the distribution chart, Align Technology ranks #239 out of 512 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Align Technology has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Align Technology's EV-to-EBITDA compare to BAX and SOLV?
According to the Medical Devices & Instruments industry distribution chart, Align Technology ranks #239 out of 512 companies for EV-to-EBITDA. This puts Align Technology in the upper half of its industry. The industry median EV-to-EBITDA is 14.39. Align Technology's value of 13.84 is 3.8% below this benchmark. Historically, Align Technology's own EV-to-EBITDA has ranged from 10.56 to 101.03 over the past decade. While the company's 10-year median is 30.78 vs. the industry median of 14.39, Align Technology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.39, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Align Technology's current EV-to-EBITDA of 13.84 is 3.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Align Technology. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Align Technology's current EV-to-EBITDA is 13.84, which is 55% below median its own 10-year median of 30.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Align Technology stock overvalued right now?
Based on GuruFocus' analysis, Align Technology (XTER:AFW) is currently considered Modestly Undervalued. The stock's GF Value™ is €215.66, compared to a current price of €151.70 — trading 29.7% below its estimated fair value. The current EV-to-EBITDA is 13.84, which is 55% below median its 10-year median of 30.78 and 3.8% below the Medical Devices & Instruments industry median of 14.39. Align Technology's overall GF Score™ is 85/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Align Technology (XTER:AFW), the current EV-to-EBITDA is 13.84 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Align Technology (XTER:AFW) Overvalued in 2026?
Based on GuruFocus' analysis, Align Technology stock appears to be undervalued.
The current stock price of €151.70 is trading 29.7% below its estimated GF Value™ of €215.66.
GuruFocus considers Align Technology to be Modestly Undervalued.
Key valuation signals for XTER:AFW:
EV-to-EBITDA: 13.84 (55% below median its 10-year median of 30.78)
GF Value™: €215.66 vs. price of €151.70 (29.7% below fair value)
Industry Position: 3.8% below the Medical Devices & Instruments median (#239 of 512)
No single metric tells the full story. See the XTER:AFW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.
85GF Score
Get the complete analysis for XTER:AFW
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:AFW has been successfully added to your 
